Plain-English translation of NCT05239546 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an immunotherapy drug, to see if it can effectively shrink colon tumors that have a specific genetic feature called mismatch repair deficiency. The goal is to determine whether patients can avoid surgery altogether if the medication works well, or have surgery as a backup option if the tumor doesn't respond.
Standard treatment for stage II and III colon cancer typically involves surgery, which can have significant side effects and impact quality of life. This trial explores whether this medication can control these tumors without surgery, offering patients a less invasive option.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion every 3 weeks for 6 doses, then every 6 weeks for 8 additional doses, continuing for about 1.5 years total. Throughout this time, your doctors will monitor your tumor with imaging and blood tests to see if the treatment is working. If your tumor shrinks significantly and meets the study's success criteria, you may avoid surgery entirely; if it doesn't respond adequately, you would proceed to surgery as planned.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Iowa
Enrollment target
~25 participants
Started
March 2023
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Saima Sharif, MD, MS
University of Iowa Holden Comprehensive Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.